Ambien CR launch takes hold

Share this article:
A controlled release version of the Sanofi-Aventis anti-insomnia drug zolpidem, Ambien CR has reached pharmacy shelves, the company said.
The new pill, launched October 7, is being introduced to doctors by a force of 3,500 sales reps, the firm noted.
Sanofi-Aventis is hoping CR receives a warm welcome, as top-selling Ambien is set to move off patent next year. Brand communications emphasize its indication for sleep maintenance, as well as sleep induction. Publicis' Saatchi & Saatchi family of agencies handles med ed, consumer and professional ads.
Ambien had U.S. third-quarter sales of 371 million euros ($437 million), up 4.8% from the same quarter last year, according to the drug maker. U.S. sales for the nine months ending in September reached 948 million euros ($1.1 billion), an increase of 8.8%.
The Ambien franchise faces competition from two other recently launched prescription sleep aids, Rozerem (ramelteon) from Takeda Pharmaceuticals North America and Sepracor's Lunesta (eszopiclone).
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.

Five things for Pharma Marketers to Know: Thursday, August 28

Five things for Pharma Marketers to Know: Thursday, ...

Human testing of GSK's Ebola virus starts next week, menopause is a costly healthcare concern, and a small conversation with pharmacists may have a big impact.